Olanzapine Orally Disintegrating Tablets — Class III drug recall D-0066-2021
Terminated recall by Jubilant Cadista Pharmaceuticals, Inc., reported 2020-11-11, distributed nationwide. Subpotent
| Recall number | D-0066-2021 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Jubilant Cadista Pharmaceuticals, Inc., Salisbury, MD, United States |
| Recall initiated | 2020-10-26 |
| Classified | 2020-11-05 |
| Reported by FDA | 2020-11-11 |
| Terminated | 2021-08-11 |
| Distributed | Nationwide (US) |
| Quantity | 23,616 blister |
| Reason classes | potency |
| NDC | 59746-0306-32 |
| Lot numbers | AE119001A |
| Expiration dates | 2021-01 |
Product
Olanzapine Orally Disintegrating Tablets, 5 mg, 30 count (3x10 unit dose) blister pack, Rx only, Manufactured by: Jubilant Generics, Ltd., Roorkee, India, Marketed by: Jubilant Cardista Pharmaceuticals, Inc., Salisbury, MD NDC 59746-0306-32
Reason for recall
Subpotent
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0066-2021. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.